Step 9 semaglutide: what reaching the 2.4 mg Wegovy dose actually means

You have just injected your ninth weekly dose, here is what has changed

Picture this: you set a reminder for the same day each week, you have kept to it, and you are now holding a Wegovy pen loaded with 2.4 mg. That is not a small thing. The preceding eight steps (0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, each held for roughly four weeks before the prescriber considered moving up) were specifically designed to reduce the nausea and digestive discomfort that semaglutide can cause when introduced too quickly. By the time you reach step 9, your gut has had months to adapt.

At 2.4 mg, semaglutide is working at the dose studied most extensively in clinical trials. The NHS semaglutide page describes the medicine's action: it mimics GLP-1, a hormone released after eating, slowing gastric emptying and reducing appetite. At the maintenance dose, those effects are operating at their full licensed intensity. Some people notice a distinct drop in interest in food around this transition; others find the change more gradual. Both are reported.

Side effects at step 9 are not necessarily worse than at earlier steps. Gastrointestinal symptoms (loose stools, nausea, burping, indigestion) tend to be most pronounced during and just after dose increases, then settle. If they remain disruptive at 2.4 mg, the right move is a conversation with your prescriber, not a self-managed change to timing or dose. Nothing in this article replaces that conversation. Your Patient Information Leaflet and the advice of your clinical team are the authoritative guides on what to do if symptoms persist.

What the 2.4 mg step was designed to achieve, and how results tend to unfold

Clinically, 2.4 mg is where Wegovy was licensed to deliver its weight-management benefit. The STEP 1 trial enrolled adults without diabetes, and participants who reached and stayed at this dose saw average losses of around 15% of body weight across 68 weeks, with those who stayed fully adherent to both the medicine and lifestyle changes seeing somewhat greater reductions. It is worth sitting with the word "average": some participants lost considerably more, others less. Weight loss at step 9 is not a switch that flips; it accumulates over months.

The months immediately after reaching step 9 are often where the most visible progress happens, precisely because the medicine is finally at its target concentration and the body is still responding. Progress can plateau later, that is a normal physiological response, not treatment failure. Continued engagement with diet, protein intake and activity remains relevant throughout, which is why the NHS frames these medicines as working alongside lifestyle changes rather than instead of them.

For context on what the full treatment journey looks like, the semaglutide titration overview covers the whole schedule, and the Wegovy treatment page explains how the medicine is used across all of its licensed indications. If you are weighing up how semaglutide compares to other options available in the UK, the weight-loss treatments overview sets out what is currently licensed.

Clinical review at step 9: what a prescriber looks at before continuing

Reaching step 9 is not the end of clinical oversight, it is a continuation of it. At each repeat, a prescriber assesses whether continuing at 2.4 mg remains appropriate. The question they are asking is roughly: has there been meaningful progress, is the person tolerating the dose well, and are there any new clinical factors to consider? NICE's guidance on semaglutide for weight management notes that if weight loss of less than 5% has occurred after six months at the maintenance dose, continuing should be reviewed. That is a clinical decision, not an automatic stop, and context matters significantly.

Transfer patients arriving at step 9 from another provider need to supply evidence of their current dose and treatment history before a prescriber will continue at that level. This is standard clinical practice, not a complication; it protects the patient. At nume, every repeat order for Wegovy is reviewed by a GPhC-registered prescriber, a clinician reads the information, not an automated system. The clinical team operates the same-day review model across all steps of treatment, including maintenance.

One practical note worth raising: the timing of your repeat order matters. Orders placed before midday Monday to Friday, once clinically approved, are dispatched the same day for free next-working-day delivery. If your injection day falls on a Tuesday, placing your order the Friday before keeps the rhythm uninterrupted. The FAQs cover what to do if a delivery is delayed, a question worth reading before you need it.

Step 9 and what comes after: the Wegovy 7.2 mg option

For some time, 2.4 mg was simply the ceiling. That changed in early 2026. The MHRA approved a 7.2 mg dose of Wegovy, initially supplied as three 2.4 mg pens used in the same week, and then as a dedicated single-dose pen approved on 14 April 2026. Trial data at 7.2 mg showed average weight losses of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest dose. This higher-dose option is licensed for adults with a BMI of 30 or above, and reaching it follows a titration pathway that begins from step 1, the same 0.25 mg starting point, as you can read about on our step 2 semaglutide page for an early example of how that progression works.

Not everyone will be a candidate for 7.2 mg, and the decision sits entirely with a prescriber based on individual clinical factors. It is not an automatic next step after reaching 2.4 mg. If you are considering whether a higher dose might be appropriate for you, that is a question for your next clinical review rather than something to pursue independently. For a broader picture of the semaglutide options currently available in the UK (injection and, as of June 2026, tablet) the semaglutide overview page is a useful starting point, and the team can point you in the right direction if you have specific questions about your treatment.

If you are not yet on treatment and are curious about whether Wegovy might be suitable, checking your eligibility with our prescribers is the straightforward next step.